Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
Journal Article
Athyros, V. G., Tziomalos K., Mikhailidis D. P., Pagourelias E. D., Kakafika A. I., Skaperdas A., et al. (2007).  Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother. 8(14), 2267-77.
Athyros, V. G., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2008).  Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 200(1), 1-12.
Karagiannis, A., Mathiopoulou L., Tziomalos K., Kontotasios K., Skaperdas A., Florentin M., et al. (2006).  Dry cough as first manifestation of giant-cell arteritis.. J Am Geriatr Soc. 54(12), 1957-8.
Kakafika, A. I., Liberopoulos E. N., Karagiannis A., Athyros V. G., & Mikhailidis D. P. (2006).  Dyslipidaemia, hypercoagulability and the metabolic syndrome.. Curr Vasc Pharmacol. 4(3), 175-83.
Mikhailidis, D. P., & Athyros V. G. (2014).  Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.. Nat Rev Cardiol. 11(2), 72-4.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.. Open Cardiovasc Med J. 5, 24-34.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Dyslipidemia as a risk factor for ischemic stroke.. Curr Top Med Chem. 9(14), 1291-7.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.. Open Cardiovasc Med J. 5, 85-9.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.
Athyros, V. G., Katsiki N., Karagiannis A., & Radak D. (2015).  Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy.. Curr Vasc Pharmacol. 13(2), 223-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2015).  Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease.. Curr Vasc Pharmacol. 13(3), 366-7.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).. Curr Vasc Pharmacol. 12(6), 867-9.
Athyros, V. G., & Doumas M. (2018).  Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.. Curr Vasc Pharmacol. 16(3), 206-208.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Editorial: (Persistent elevation of blood pressure in children and adolescents is associated with arterial hypertension and premature atherosclerosis in adults. Is it possible to reverse this?).. Curr Vasc Pharmacol. 12(6), 870-2.
Athyros, V. G., Katsiki N., & Doumas M. (2018).  Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.. Curr Vasc Pharmacol. 16(2), 104-106.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 10(3), 374-7.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII.. Curr Vasc Pharmacol. 13(6), 696-8.
Imprialos, K., Doumas M., Tokamani M., Sandaltzopoulos R., & Athyros V. G. (2017).  Editorial: The microRNA 221/222 Cluster: Inaugurating a New Era in Cardiovascular Disease and Cancer?. Curr Vasc Pharmacol. 15(1), 47-50.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2016).  Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs.. Curr Vasc Pharmacol. 14(2), 208-10.
Anagnostis, P., Siolos P., Christou K., Gkekas N. K., Kosmidou N., Athyros V. G., et al. (2018).  The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.. Hormones (Athens). 17(1), 83-95.
Karagiannis, A., Tziomalos K., Anagnostis P., Gossios T. D., Florentin M., Athyros V. G., et al. (2010).  The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.. Curr Vasc Pharmacol. 8(6), 792-803.
Karagiannis, A., Tziomalos K., Pagourelias E. D., Gossios T. D., & Athyros V. G. (2010).  Effect of antihypertensive drug-associated diabetes on cardiovascular risk.. Hellenic J Cardiol. 51(3), 195-9.
Mitsiou, E., Boutari C., Kotsis V., Georgianou E., Doumas M., Karagiannis A., et al. (2018).  Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.. Curr Vasc Pharmacol. 16(4), 393-400.
Athyros, V. G., Mikhailidis D. P., Didangelos T. P., Giouleme O. I., Liberopoulos E. N., Karagiannis A., et al. (2006).  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.. Curr Med Res Opin. 22(5), 873-83.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές